QUOTE AND NEWS
TheStreet.com  Apr 10  Comment 
NEW YORK (TheStreet) -- Shares of DexCom Inc.  are up 1.2% to $38.74 after Sterne Agee upgraded the medical device company to "buy" from "neutral" with a price target of $50. "We believe DexCom will once again record strong annual revenue growth...
SeekingAlpha  Mar 25  Comment 
By Andy Batts: In my last article on DexCom (DXCM) back in June last year, I argued that the stock could be a potential multi-bagger. The stock was then trading just below $22. Earlier this month, DXCM created an all-time high of $49.83 before...
SeekingAlpha  Feb 21  Comment 
DexCom, Inc. (DXCM) Q4 2013 Results Earnings Conference Call February 20, 2014, 04:30 AM ET Executives Terrance H. Gregg - Chief Executive Officer Steven R. Pacelli - Executive Vice President, Strategy and Corporate Development ...
StreetInsider.com  Feb 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/DexCom%2C+Inc.+%28DXCM%29+Tops+Q4+EPS+by+3c/9198028.html for the full story.
SeekingAlpha  Feb 20  Comment 
Complete Story »
TheStreet.com  Feb 6  Comment 
This content brought to you by TheStreet's OptionsProfits. CLICK HERE FOR A 14-DAY FREE TRIAL. As the daughter of an insulin-dependent mother who receives 24-hour treatment via catheter insulin pump therapy, diabetes management and technology is...
MedPage Today  Feb 4  Comment 
(MedPage Today) -- Use of the Dexcom G4 Platinum continuous glucose monitor has been expanded to include children ages 2 to 17, the FDA said in a statement.
DailyFinance  Jan 7  Comment 
DexCom, Inc. (NASDAQ:DXCM) today announced that Terry Gregg, Chief Executive Officer, will present an update on the company at the J.P. Morgan 2014 Healthcare Conference in San Francisco on Tuesday, January 14, 2014 at 3:30pm...
Market Intelligence Center  Jan 3  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on DexCom (DXCM). Look at the Jun. '14 $30.00 covered call for a net debit in the $28.45 area. This trade has a duration of 169...
Market Intelligence Center  Jan 2  Comment 
Option-trade picking algorithms patented by MarketIntelligenceCenter.com found a trading opportunity with DexCom (DXCM) that should provide a 4.92% return in just 51 days. Sell one Feb. '14 call at the $35.00 level for each 100 shares of DexCom...




 

DXCM, based in San Diego, California, is an emerging medical device company focused on the design and development of continuous glucose monitoring(CGM) systems for people with diabetes. The company is currently engaged in the development of two continuous glucose-monitoring systems: a short-term system with a sensor that can be inserted by a patient, and a long-term system with a sensor that can be implanted by a physician. A key element of DXCM's monitoring system technology is the continuous measure of patient's blood glucose level and the real-time transmission of that information to a small cell phone-sized receiver. DXCM's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alert patients to assist in managing their blood glucose levels. In contrast, currently available self-monitoring systems use disposable test strips to test blood sampled at discrete points in time.

History & Products

The company was founded in 1999 and listed on April 19, 2005 through the issue of 4,700,000 shares of common stock, raising $52.5M. DXCM has eight issued U.S. patents expiring between 2006 and 2021, and 60 additional U.S. patent applications pending. In 1Q06 DXCM received Food and Drug Administration (FDA) approval for its STS Continuous Glucose Monitoring System, which was subsequently launched nationally on March 28, 2006.

The SEVEN System

The SEVEN System is presented as an alternative to the "finger-stick" method of glucose monitoring. By using continuous glucose monitoring(CGM) individuals who would normally monitor their levels via infrequent testing throughout the day can track their glucose levels as a trend from moment to moment. The SEVEN System is made up of three components: the sensor, the transmitter and the receiver; and are designed to be small, unobtrusive, and lightweight. Comparison with competitive products can be viewed below in "Competition."

DexCom Data Manager 2

Designed to analyze downloaded data from the SEVEN receiver, DexCom's diabetes management software provides users to track their trends and progress over time. This includes the ability to plot CGM values across several days and overlaid on the target range for comprehensive lifestyle evaluation.

Business & Financials

Trends & Forces

Competition

[1] DexCom SEVEN System Freestyle Navigator Guardian RT
Hypo-Safety-Alarm Yes, less than or equal to 55 mg/dL (Cannot be turned off) No No
Sensor life Up to 7 days Up to 5 days Up to 3 days
Sensor warm-up time after calibration 2 hours 10 hours 2 hours
Average lag time 5 minutes 14 minutes Not documented
Calibration (minimum requirement) Twice a day 4 times over 5 days Twice a day
Introducer needle size (diameter) .5mm (26 gauge) .72mm (21 gauge) .65mm (22 gauge)
Transmitter weight 6.8 grams 13.6 grams 7.1 grams
Transmitter power Built in and lasts for life of Transmitter (1.5 Years) Battery cell must be replaced Rechargeable
Receiver power Rechargeable Battery lasts about 30 days Battery lasts about 2 to 4 weeks
Calibration restrictions Accepts calibration values between 40-400 mg/dL Accepts calibration values between 60-300 mg/dL. No calibrations during or around meals, exercise, or while sleeping. Accepts calibration values between 40-400 mg/dL. No calibrations with changing glucose values.

WikiData

References

  1. DexCom Product Comparison
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki